IBRX News

Pomerantz LLP Highlights Class Action Against ImmunityBio, Inc. – IBRX

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - IBRX

IBRX Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages IBRX Investors with Losses to Contact the Firm

INVESTOR NOTICE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action - Hagens Berman

Deadline Alert: ImmunityBio, Inc. (IBRX) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

IBRX EQUITY ALERT: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026 Ready to Announce with Confidence?

IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky

IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Calls Attention to Class Action Against ImmunityBio, Inc. – IBRX